Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EDITNASDAQ:FATENASDAQ:HLVXNYSE:JATT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$5.55-1.1%$7.85$5.51▼$11.91$454.05M2.011.82 million shs1.71 million shsFATEFate Therapeutics$5.04-4.4%$6.95$1.63▼$8.83$500.17M1.662.78 million shs2.33 million shsHLVXHilleVax$11.86-5.3%$16.09$9.94▼$20.22$623.00M0.65135,947 shs1.14 million shsJATTJATT Acquisition$3.69+17.9%$3.65$7.80▼$12.38$63.65MN/A41,322 shs1.01 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-4.10%-15.38%-27.33%-31.33%-30.40%FATEFate Therapeutics-2.04%-15.95%-25.14%+21.71%-15.41%HLVXHilleVax-3.69%-10.95%-27.78%-13.88%-9.73%JATTJATT Acquisition-3.18%+9.75%-62.75%-24.57%-68.66%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine3.3533 of 5 stars3.31.00.04.61.92.50.0FATEFate Therapeutics4.2091 of 5 stars4.01.00.04.72.62.50.6HLVXHilleVax3.6091 of 5 stars3.55.00.00.03.25.00.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine2.56Moderate Buy$15.00170.27% UpsideFATEFate Therapeutics2.08Hold$6.7333.48% UpsideHLVXHilleVax3.00Buy$30.67158.57% UpsideJATTJATT AcquisitionN/AN/AN/AN/ACurrent Analyst RatingsLatest FATE, EDIT, HLVX, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold3/28/2024FATEFate TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$2.00 ➝ $6.003/21/2024HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/19/2024FATEFate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.002/29/2024EDITEditas MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $16.002/29/2024EDITEditas MedicineBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $11.002/27/2024EDITEditas MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.002/27/2024FATEFate TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $7.002/27/2024FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $10.002/27/2024FATEFate TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$6.00 ➝ $7.002/27/2024FATEFate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $7.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$78.12M5.81N/AN/A$4.27 per share1.30FATEFate Therapeutics$63.53M7.87N/AN/A$3.74 per share1.35HLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/AJATTJATT AcquisitionN/AN/A$0.14 per share27.08($0.53) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$2.05N/AN/AN/A-196.12%-42.95%-30.49%5/3/2024 (Estimated)FATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-253.30%-38.17%-28.42%5/1/2024 (Estimated)HLVXHilleVax-$123.57M-$3.04N/AN/AN/AN/A-48.17%-38.05%5/10/2024 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALatest FATE, EDIT, HLVX, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023HLVXHilleVax-$0.80-$0.78+$0.02-$0.78N/AN/A2/28/2024Q4 2023EDITEditas Medicine-$0.52-$0.23+$0.29-$0.23$4.84 million$60.00 million 2/26/202412/31/2023FATEFate Therapeutics-$0.57-$0.45+$0.12-$0.45$0.85 million$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A5.395.39FATEFate TherapeuticsN/A8.488.48HLVXHilleVax0.1010.6210.62JATTJATT AcquisitionN/A0.150.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FATEFate Therapeutics97.54%HLVXHilleVax86.42%JATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine2.20%FATEFate Therapeutics5.04%HLVXHilleVax29.30%JATTJATT Acquisition20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine26581.81 million80.01 millionOptionableFATEFate Therapeutics18199.24 million94.24 millionOptionableHLVXHilleVax9049.72 million35.15 millionNot OptionableJATTJATT Acquisition2,02117.25 million13.80 millionNot OptionableFATE, EDIT, HLVX, and JATT HeadlinesSourceHeadlineBahdarpur Jatt Pin Codeindiatvnews.com - April 10 at 12:34 AMNishikant Dubey, wife booked in med college acquisition casetimesofindia.indiatimes.com - March 31 at 7:56 PMSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. Steelpennlive.com - December 22 at 12:48 PMMicrosoft poised to close massive Activision Blizzard acquisition next weekvg247.com - October 9 at 6:20 PMThe Legend of Maula Jatt to be released in cinemas on Thursdayradio.gov.pk - July 8 at 10:17 AMPakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp Belgiumradio.gov.pk - June 15 at 7:58 AMZura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upsidemsn.com - May 24 at 5:21 PMI Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The Twoscoopwhoop.com - April 28 at 7:22 PMZura Bio Announces Appointment of Chief Scientific Officerbusinesswire.com - April 16 at 10:12 AMTalkTalk, the Issa brothers and AO: The 19 latest deals from across the North Westmsn.com - March 30 at 10:10 AMZura Bio Limited Announces Share Redemptions and Lock-up Agreementfinance.yahoo.com - March 27 at 1:00 PMTesla, Coinbase, Chewy, JATT Acquisition, Manchester United: Why These 5 Stocks Are Drawing Investors' Attention Todaybenzinga.com - March 23 at 12:27 AMCheshire biotech start-up raises $65m in New York float in further snub to London Stock Exchangemsn.com - March 21 at 7:04 PMNewly public Zura Bio stock falls 11% following Nasdaq debutseekingalpha.com - March 21 at 7:04 PMAnother British tech firm opts for a New York listing as UK’s science superpower dreams fadecityam.com - March 21 at 9:03 AMZura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corpfinance.yahoo.com - March 21 at 9:03 AMA gandasa from 'The Legend of Maula Jatt' auctioned for $50,000tribune.com.pk - March 17 at 7:19 PMJATT Acquisition shareholders approve business combination with Zura Biomsn.com - March 16 at 7:03 PMJATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limitedfinance.yahoo.com - March 16 at 7:03 PMJATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limitedbusinesswire.com - March 13 at 9:33 AMSPAC JATT to hold shareholders vote on Zura Bio merger on March 16msn.com - March 2 at 3:17 PMJATT Acquisition Corp’s Proposed Business Combination With Zura Bio Limited Declared Effective by US SECfinance.yahoo.com - March 2 at 3:17 PMJATT Acquisition Corp (NYSE:JATT) is a favorite amongst institutional investors who own 54%finance.yahoo.com - February 25 at 11:59 AMElon Musk reportedly planning to cut 50% jobs at Twitter: reporttimesnownews.com - October 31 at 5:38 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeRobinhood’s Credit Card Has Call Option Buyers Coming in HotApril 3, 2024 8:45 AMView Robinhood’s Credit Card Has Call Option Buyers Coming in HotHere are the Pros and Cons of Using Options Put Credit Spreads April 18, 2024 8:20 AMView Here are the Pros and Cons of Using Options Put Credit Spreads All Headlines Company DescriptionsEditas MedicineNASDAQ:EDITEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Fate TherapeuticsNASDAQ:FATEFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.HilleVaxNASDAQ:HLVXHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.JATT AcquisitionNYSE:JATTJATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.